Skip to main content

Abstract

1. Stop injection/infusion immediately

2. Get extravasation kit

3. Put on (sterile) gloves

4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Original articles

  1. Dorr RT, Alberts DS: Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents. Invest New Drugs 1: 151–159, 1983.

    Article  PubMed  CAS  Google Scholar 

  2. Krämer I: Zehn Jahre Dokumentation von Zytostatika-Paravasat-Ereignissen: Auswertung von 175 Paravasate-Dokumentationen. Krankenhauspharmazie 23: 269–274, 2002.

    Google Scholar 

Secondary literature

  1. Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.

    Article  PubMed  CAS  Google Scholar 

  2. Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.

    Article  PubMed  CAS  Google Scholar 

  3. Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.

    Google Scholar 

  4. Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154–160, 1992.

    Google Scholar 

  5. Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.

    Google Scholar 

  6. Donislawski S, Gain M, Meyer-Jürshof A, et al: Etoposid: Behandlung von Paravasaten. In: Donislawski S, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Mono-graphien. Verlag Heiner Biller, vol 2: 33, 1994.

    Google Scholar 

  7. Bristol-Myers Squibb, personal communication, January 1999.

    Google Scholar 

  8. Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.

    Google Scholar 

  9. Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.

    Article  PubMed  CAS  Google Scholar 

  10. Bokemeyer C: Dermatoxizität antineoplastischer Substanzen. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, vol 1, 3rd edition: 1411–1426, 1999.

    Google Scholar 

  11. Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 1, 2nd edition: A42–44, 1997.

    Google Scholar 

  12. Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.

    Google Scholar 

  13. Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.

    PubMed  CAS  Google Scholar 

  14. Barth J: Paravasate und deren Behandlung. In: Barth J (ed) -Zytostatika-Herstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.

    Google Scholar 

  15. Dorr RT, Von Hoff DD: Drug monographs: etoposide. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 459–472, 1994.

    Google Scholar 

  16. Summary of product characteristics Vepesid® (Germany), -Bristol-Myers Squibb, February 2005.

    Google Scholar 

  17. Albanell J, Baselga J: Systemic therapy emergencies. Semin Oncol 27: 347–361, 2000.

    PubMed  CAS  Google Scholar 

  18. Ener RA, Meglathery SB, Styler M: Extravasation of systemic hemato-oncological therapies. Ann Oncol 15: 858–862, 2004.

    Article  PubMed  CAS  Google Scholar 

  19. Alley E, Green R, Schuchter L: Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14: 212–216, 2002.

    Article  PubMed  CAS  Google Scholar 

  20. Koppel RA, Boh EE: Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 321: 327–335, 2001.

    Article  PubMed  CAS  Google Scholar 

  21. Krämer I, Stützle M: Zytostatika-Paravasation – Wie ist vorzu-gehen? Krankenhauspharmazie 23: 261–268, 2002.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag/Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). Etoposide. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-88893-3_33

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-88889-6

  • Online ISBN: 978-3-211-88893-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics